These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3493 related articles for article (PubMed ID: 23107319)

  • 1. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.
    Korkolopoulou P; Levidou G; El-Habr EA; Piperi C; Adamopoulos C; Samaras V; Boviatsis E; Thymara I; Trigka EA; Sakellariou S; Kavantzas N; Patsouris E; Saetta AA
    Histopathology; 2012 Aug; 61(2):293-305. PubMed ID: 22690797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.
    Sun CH; Chang YH; Pan CC
    Histopathology; 2011 Jun; 58(7):1054-63. PubMed ID: 21707707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides.
    Levidou G; Siakantaris M; Papadaki T; Papadavid E; Vassilakopoulos TP; Angelopoulou MK; Marinos L; Nikolaou V; Economidi A; Antoniou C; Patsouris E; Korkolopoulou P
    J Am Acad Dermatol; 2013 Sep; 69(3):375-84. PubMed ID: 23685026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma.
    Tasioudi KE; Sakellariou S; Levidou G; Theodorou D; Michalopoulos NV; Patsouris E; Korkolopoulou P; Saetta AA
    APMIS; 2015 Aug; 123(8):639-47. PubMed ID: 25912437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma.
    Setsu N; Kohashi K; Fushimi F; Endo M; Yamamoto H; Takahashi Y; Yamada Y; Ishii T; Yokoyama K; Iwamoto Y; Oda Y
    Cancer; 2013 Oct; 119(19):3504-13. PubMed ID: 23861137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
    Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
    Hafner C; Landthaler M; Vogt T
    Exp Dermatol; 2010 Aug; 19(8):e222-7. PubMed ID: 20557351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
    Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
    Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the Akt/mammalian target of rapamycin pathway in myxofibrosarcomas.
    Takahashi Y; Kohashi K; Yamada Y; Endo M; Setsu N; Ishii T; Yamamoto H; Iwamoto Y; Oda Y
    Hum Pathol; 2014 May; 45(5):984-93. PubMed ID: 24746202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Akt/mTOR/4E-BP1 pathway signal activation and mutations of PIK3CA in Merkel cell polyomavirus-positive and Merkel cell polyomavirus-negative carcinomas.
    Iwasaki T; Matsushita M; Nonaka D; Kuwamoto S; Kato M; Murakami I; Nagata K; Nakajima H; Sano S; Hayashi K
    Hum Pathol; 2015 Feb; 46(2):210-6. PubMed ID: 25466966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder.
    Nishikawa M; Miyake H; Behnsawy HM; Fujisawa M
    Urol Oncol; 2015 Apr; 33(4):166.e9-15. PubMed ID: 25618298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development.
    El-Habr EA; Levidou G; Trigka EA; Sakalidou J; Piperi C; Chatziandreou I; Spyropoulou A; Soldatos R; Tomara G; Petraki K; Samaras V; Zisakis A; Varsos V; Vrettakos G; Boviatsis E; Patsouris E; Saetta AA; Korkolopoulou P
    Virchows Arch; 2014 Oct; 465(4):473-85. PubMed ID: 25146167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
    Nathan CO; Amirghahari N; Abreo F; Rong X; Caldito G; Jones ML; Zhou H; Smith M; Kimberly D; Glass J
    Clin Cancer Res; 2004 Sep; 10(17):5820-7. PubMed ID: 15355912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer.
    Nawroth R; Stellwagen F; Schulz WA; Stoehr R; Hartmann A; Krause BJ; Gschwend JE; Retz M
    PLoS One; 2011; 6(11):e27509. PubMed ID: 22110663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma.
    Liu D; Huang Y; Chen B; Zeng J; Guo N; Zhang S; Liu L; Xu H; Mo X; Li W
    Cancer; 2011 Aug; 117(16):3763-73. PubMed ID: 21387259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
    Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
    Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 175.